Submitted Successfully!
Thank you for your contribution! You can also upload a video entry related to this topic through the link below: https://encyclopedia.pub/user/video_add?id=33103
Check Note
2000/2000
Ver. Summary Created by Modification Content Size Created at Operation
1 -- 3115 2022-11-04 18:02:47 |
2 layout Meta information modification 3115 2022-11-07 09:54:57 | |
3 layout Meta information modification 3115 2022-11-07 09:55:14 |
Conventional Anti-Inflammatory Drugs of Major Depressive Disorder
Edit
Upload a video

Major depressive disorder (MDD) is characterised by symptoms such as depressed mood, anhedonia, appetite and sleep dysfunctions, psychomotor agitation or retardation, fatigue, feelings of worthlessness, thinking or concentration problems and suicidal ideation. Its impact on health can be dramatic, as it increases the risk of cardiovascular disease, stroke, diabetes and obesity, and suicide is one of the leading causes of death, especially in the 15–29 age group. Moreover, treatment-resistant depression is an important challenge in clinical practice since 10–30% of patients are refractory to several standard antidepressant medications and have a decreased quality of life.

depression anti-inflammatory NSAID cytokine inhibitor
Information
Subjects: Neurosciences
Contributors : , , ,
View Times: 40
Revisions: 3 times (View History)
Update Time: 07 Nov 2022
Table of Contents

    1. Introduction

    Major depressive disorder (MDD), often referred to as unipolar depression, is an important public health issue nowadays, affecting around 280 million people worldwide, which corresponds to approximately 3.8% of the population [1]. Patients with MDD experience only major depressive episodes, while patients with bipolar disorder exhibit mood fluctuations which encompass depressive episodes, known as bipolar depression in this case, and episodes of mania or hypomania [2]. MDD is characterised by symptoms such as depressed mood, anhedonia, appetite and sleep dysfunctions, psychomotor agitation or retardation, fatigue, feelings of worthlessness, thinking or concentration problems and suicidal ideation [3]. Its impact on health can be dramatic, as it increases the risk of cardiovascular disease, stroke, diabetes and obesity [4], and suicide is one of the leading causes of death, especially in the 15–29 age group [1]. Moreover, treatment-resistant depression is an important challenge in clinical practice since 10–30% of patients are refractory to several standard antidepressant medications and have a decreased quality of life [5]. Considering the various implications of this disorder, which far exceed those listed here, the constant need for developing new and efficacious therapeutic strategies seems perfectly justified.
    Current medications approved for treating MDD are selective serotonin reuptake inhibitors—SSRIs, serotonin and norepinephrine reuptake inhibitors—SNRIs, tricyclic antidepressants—TCAs, monoamine oxidase inhibitors—MAOIs, N-Methyl-D- aspartate (NMDA) receptor antagonists, serotonin modulators and atypical antidepressants. They are thought to exert their actions mainly by increasing the available synaptic serotonin and/or norepinephrine [6]. This mechanism is based on the monoaminergic theory of depression, which states that a decrease in serotonin, norepinephrine and dopamine is responsible for this pathology. Chronologically, it is the first proposed theory (hence the inherent limitations of these drugs) [7]. However, with immunology as a rapidly emerging field and inflammation incriminated as an underlying cause of many diseases [8], there is growing evidence for a putative link between inflammation and depression. This finding holds promise for new possible approaches in addressing this challenging disorder [9]. Interestingly, SSRIs and SNRIs were proved to have an anti-inflammatory role in the central nervous system (CNS) which may play a part in the antidepressant effect [10].
    Depression was shown to be associated with morphofunctional changes at the level of various brain areas, such as the frontal and parietal cortex, the hippocampus, the thalamus or the striatum [11]. These changes represent the substrate for the cognitive and behavioural impairments seen in this pathology. For example, striatal gray matter alterations are correlated with suicidality [12], whereas dysfunctions of the prefrontal cortex–amygdala–hippocampus circuitry possibly connected with neurovisceral structures lead to abnormal fear conditioning [13][14]. Regarding inflammatory depression, structural and functional changes in the aforementioned brain regions were identified in the context of elevated peripheral inflammatory biomarkers [15]. For instance, increased C-reactive protein (CRP) is associated with a dysfunctional corticostriatal reward circuit—a key component of treatment-resistant depression [16]. At the molecular level, neuronal impairment could be explained by the direct neurotoxic effect of inflammatory cytokines. Moreover, cytokines appear to stimulate the tryptophan-kynurenine-quinolonic acid pathway, inducing excitotoxicity [15]. Indeed, there is increasing evidence for kynurenine pathway activation in MDD patients [17].
    Mechanistic explanations for inflammation-associated depression relate to the action of cytokines on basal ganglia [18] and several polymorphisms in cytokine genes were associated with depression and response to antidepressants [19]. Sometimes, inflammatory depression is even discussed as an entirely particular subtype of depression and seems to be correlated with the prevalence of certain symptoms, such as hypersomnia, fatigue, or increased appetite. These symptoms also belong to the “atypical” subtype, which occurs in approximately 15–30% of patients [4]. Atypical depression was shown to be connected with inflammation, although some results were not consistent [20]. Of note, obesity and metabolic syndrome (inflammation-related conditions) are common findings in patients presenting with this subtype [21]. Fatigue might also be the expression of “sickness behaviour”. This energy-conserving adaptive response to infections and other inflammation-inducing situations displays similarities with depression [22]. As opposed to the atypical subtype, melancholic depression features reduced pro-inflammatory cytokines, except for exacerbations [23]. Finally, inflammation was also associated with treatment-resistant depression [24]. All these findings underline the heterogeneous nature of depression and support the need for an individualised approach to patients exhibiting different clinical pictures.

    2. Conventional Anti-Inflammatory Drugs

    2.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

    Perhaps some of the most used and studied anti-inflammatory treatment options are NSAIDs. They act by inhibiting the enzymes cyclooxygenase (COX)-1 and COX-2, which promote inflammatory mediators [25]. NSAIDs divide into non-selective and selective (only inhibiting COX-2). The first category includes drugs such as aspirin, diclofenac, ibuprofen, indomethacin, meloxicam, or naproxen, whereas celecoxib and etoricoxib are notable members of the second one [26].
    Among non-selective NSAIDs, aspirin was shown to be a potentially successful add-on. It even decreased latency to SSRIs response in a pilot open-label study where 52.4% of the patients not previously responding to SSRI therapy showed clinically relevant improvement, mostly from the first week [27]. Moreover, treatment with aspirin was linked to a lower depression rate in the first year after a primary tumour diagnosis. This result was not achieved by other NSAIDs [28]. Unfortunately, there is only a small number of RCTs, with conflicting results. For instance, in a relatively recent study, the co-administration of aspirin and citalopram had to be interrupted, due to severe adverse reactions (anxiety, akathisia and even suicidal behaviour) (Table 1) [29]. However, researchers have to consider the very small number of patients included in this research and that these side effects can rather be attributed to citalopram than aspirin. While aspirin as an add-on to sertraline elicited a greater benefit than sertraline-placebo alone [30], another RCT, with escitalopram and duloxetine as concomitant medication, identified a difference only between two subgroups (i.e., duloxetine + aspirin and escitalopram + placebo). This result could also be attributed to higher baseline serum brain-derived neurotrophic factor (BDNF) in the first subgroup (Table 1) [31]. Two major trials from 2020 failed to show the benefit of aspirin in treating young MDD patients or preventing depression in the elderly. Berk et al. investigated the effects of rosuvastatin or aspirin in young people and found no advantage of the two over placebo. Furthermore, at week 12, aspirin was inferior to placebo in improving patients’ quality of life and to rosuvastatin on several parameters, including depression intensity [32]. Concerning a possible prophylactic effect of aspirin, the results of a multicentre, double-blinded RCT did not support a preventive role of low-dose aspirin in depression nor identify any change in depressive symptoms in participants with a history of this disease (Table 1) [33]. A recent meta-analysis and a systematic review attained contradictory conclusions concerning the correlation between aspirin and depression, proving the need for more extensive trials. One of them found a positive association, although infrequent, with a number needed to harm of 103 [34]. The other one demonstrated a link between aspirin and a reduced risk of developing depression [35]. To conclude, there is a clear need for further investigation, but the results are in favour of the add-on type of treatment regimen, especially in clinically depressed individuals. A summary description of the RCTs of NSAIDs in MDD can be found in Table 1.
    In turn, naproxen was beneficial in patients with comorbid osteoarthritis and not in older healthy individuals in two randomised clinical trials, proving once again the need for a pre-existing pro-inflammatory status [36][37].
    Of the selective COX-2 inhibitors, celecoxib was the most investigated as an adjunctive to antidepressants, but also in monotherapy, leading to promising results. Its effectiveness as an add-on was repeatedly proved by RCTs on patients with depression [38][39], but also with colorectal cancer [40] or with depression and comorbid brucellosis [41]. Monotherapy in patients with active osteoarthritis was also successful, similar to naproxen or ibuprofen, even if the celecoxib dose was lower than in other studies (200 versus 400 mg/day) [41]. The connection between treatment response and immunological biomarkers is supported by the correlation between interleukin (IL)-6 reduction and Hamilton Depression Rating Scale (HAM-D) score reduction [42], together with a tendency towards higher baseline macrophage migration inhibitory factor (MIF) levels in responders [43]. On the other hand, a recent RCT failed to show any benefit of celecoxib added to vortioxetine, even when patients were stratified by high-sensitive C-reactive protein (hsCRP), but it is worthy of note that other biomarkers were not examined [44].
    Various concerns are related to the use of NSAIDs in unipolar depression, as it is known that they reduce the multifunctional protein p11 levels. This protein is associated with antidepressant response and is upregulated by SSRIs by means of cytokines [18]. Thus, NSAIDs might be appropriate for enhancing treatment with TCAs or noradrenergic antidepressants, but not SSRIs [45]. Selective COX-2 inhibition promotes nitrosative and oxidative stress, decreases immunomodulator prostaglandin E2 (PGE2), and may engender psychiatric symptoms [28]. NSAIDs are also incriminated for numerous adverse effects, most notably gastrointestinal and cardiovascular [26]. However, a meta-analysis did not identify such effects associated with this particular use in depression (with limitations concerning the duration and the lack of report) [46]. It is hence argued that they might be an advantageous addition particularly in the treatment of patients at low risk of cardiovascular events, except for low-dose aspirin, which is cardioprotective [47]. Finally, a register-based study revealed that aspirin and other NSAIDs decrease the risk for early-onset depression after a first stroke episode, where inflammation is presumed to play a pivotal role. At the same time, they were associated with a high risk of depression one year after the episode, highlighting the multifaceted nature of these drugs [48]. Nonetheless, they might be considered as valuable additions to antidepressant treatment, when accounting for the patient’s characteristics (clinical depression, comorbidities, inflammatory status).
    Table 1. Summary of randomised controlled trials of NSAIDs in MDD.

    2.2. Cytokine Inhibitors

    As NSAIDs are often thought to be too “off-target”, cytokine inhibitors, which have a history of inflammatory conditions treatment, may be more suitable for the purpose under discussion. Indeed, they have been studied and proved effective, especially in the presence of such comorbidities [53][54]. A problem that arises is that it is not always clear if the reduction in depressive symptoms is direct or indirect, due to a change in the primary disease’s characteristics. For example, in a study on patients with hidradenitis suppurativa, adalimumab led to a greater improvement in participants with higher baseline pain [55].
    Supporting the theory of a separate depression subtype, they were most effective when plasma cytokine levels were increased. For instance, infliximab—a TNF antagonist, surpassed placebo in depression score reduction only in the hsCRP > 5 mg/L group. This effect was enhanced by high baseline TNF together with its soluble receptors. In contrast, placebo was superior in the baseline hsCRP ≤ 5 mg/L group [18]. Conversely, another RCT of infliximab reported an improvement in depressive symptoms which was no longer significant after eliminating the influence of ankylosing spondylitis disease activity and did not correlate with CRP levels [53]. Adalimumab and etanercept, other TNF-α antagonists, improved depression scores in patients with rheumatic (i.e., ankylosing spondylitis), Crohn’s disease, psoriasis or hidradenitis suppurativa and comorbid depressive symptoms [54][55][56][57][58]. Dupilumab, an antagonist of the receptor of IL-4, showed similar results to those of the anti-TNF-α monoclonal antibodies concerning antidepressant efficacy [59][60][61]. A summary description of the RCTs of cytokine inhibitors in patients with MDD or with depressive symptoms and comorbid medical condition can be found in Table 2.
    Several less common drugs target specific cytokines whose exact role in depression is not known, but which seem to be, sometimes, even more effective. Such is the case of ixekizumab, an IL-17A inhibitor which, according to data from a recent RCT, improved depressive symptoms in patients with psoriasis, whereas TNF-α inhibitor etanercept did not, suggesting a particular role of IL-17A in the CNS [62]. Another example, guselkumab, an IL-23 inhibitor, was investigated in psoriasis patients and was proved superior to adalimumab, maintaining its outcome on depression even after adjustment for the effects related to disease activity [63].
    There remains the threat of potentially serious side effects, such as infections, which were not identified by the previously mentioned meta-analysis conducted by Köhler et al. [46], although in the context of a small number of studies. As outlined by the existing data, cytokine inhibitors possess a more targeted effect on depression-related inflammation than those previously discussed and show some promise in alleviating depressive symptoms in specific groups, i.e., patients with pre-existing inflammatory comorbidities, but more research is needed to reveal the exact effect in MDD without comorbid medical conditions.
    Table 2. Summary of randomised controlled trials of cytokine inhibitors in patients with MDD or with depressive symptoms and comorbid medical condition.

    2.3. Corticosteroids

    Other powerful anti-inflammatory drugs, corticosteroids, have generated positive results in unipolar depression, but their serious side effects represent an important disadvantage [47]. Moreover, there is a putative correlation between this type of medication and atypical depressive syndromes [65].
    Regarding evidence in favour of an antidepressant role of corticosteroids, a 4-day course of treatment with dexamethasone in MDD patients was superior to placebo, based on HAM-D scores 14 days after the beginning of the intervention [66]. In turn, hydrocortisone produced an acute antidepressant effect compared to placebo and corticotropin-releasing hormone (CRH) in a double-blind, placebo-controlled study [67]. However, data from an RCT on cardiac surgery patients (n = 1244) revealed that a single intraoperative intravenous dose of dexamethasone does not impact depression, except for the female subgroup, which might be more affected by hypothalamic-pituitary-adrenal axis dysfunctions [68]. Moreover, in men with chronic pelvic pain syndrome, one month of treatment with oral prednisolone only led to a trend towards improving depression (quantified by Hospital Anxiety and Depression Scale), in the context of normal baseline values for these scores [69]. In patients with cancer-related fatigue, dexamethasone improved quality of life but did not exert an antidepressant effect [70].
    Eventually, the results of a network meta-analysis imply that corticosteroids have a greater antidepressant capacity than other anti-inflammatory agents, but the head-to-head comparisons identified no statistically significant difference between these classes [71].

    References

    1. Depression. Available online: https://www.who.int/news-room/fact-sheets/detail/depression (accessed on 13 November 2021).
    2. Dionisie, V.; Filip, G.A.; Manea, M.C.; Movileanu, R.C.; Moisa, E.; Manea, M.; Riga, S.; Ciobanu, A.M. Neutrophil-to-Lymphocyte Ratio, a Novel Inflammatory Marker, as a Predictor of Bipolar Type in Depressed Patients: A Quest for Biological Markers. J. Clin. Med. 2021, 10, 1924.
    3. Depression Clinical Presentation: History, Physical Examination, Major Depressive Disorder. Available online: https://emedicine.medscape.com/article/286759-clinical#b4 (accessed on 13 November 2021).
    4. Penninx, B.W.J.H.; Milaneschi, Y.; Lamers, F.; Vogelzangs, N. Understanding the Somatic Consequences of Depression: Biological Mechanisms and the Role of Depression Symptom Profile. BMC Med. 2013, 11, 129.
    5. Al-Harbi, K.S. Treatment-Resistant Depression: Therapeutic Trends, Challenges, and Future Directions. Patient Prefer. Adherence 2012, 6, 369–388.
    6. Antidepressants—StatPearls—NCBI Bookshelf. Available online: https://www.ncbi.nlm.nih.gov/books/NBK538182/ (accessed on 14 November 2021).
    7. Maffioletti, E.; Minelli, A.; Tardito, D.; Gennarelli, M. Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments. Genes 2020, 11, 1089.
    8. Kotas, M.E.; Medzhitov, R. Homeostasis, Inflammation, and Disease Susceptibility. Cell 2015, 160, 816.
    9. Sakamoto, S.; Zhu, X.; Hasegawa, Y.; Karma, S.; Obayashi, M.; Alway, E.; Kamiya, A. Inflamed Brain: Targeting Immune Changes and Inflammation for Treatment of Depression. Psychiatr. Clin. Neurosci. 2021, 75, 304–311.
    10. Dionisie, V.; Filip, G.A.; Manea, M.C.; Manea, M.; Riga, S. The Anti-Inflammatory Role of SSRI and SNRI in the Treatment of Depression: A Review of Human and Rodent Research Studies. Inflammopharmacology 2021, 29, 75–90.
    11. Zhang, F.F.; Peng, W.; Sweeney, J.A.; Jia, Z.Y.; Gong, Q.Y. Brain Structure Alterations in Depression: Psychoradiological Evidence. CNS Neurosci. Ther. 2018, 24, 994.
    12. Dombrovski, A.Y.; Siegle, G.J.; Szanto, K.; Clark, L.; Reynolds, C.F.; Aizenstein, H. The Temptation of Suicide: Striatal Gray Matter, Discounting of Delayed Rewards, and Suicide Attempts in Late-Life Depression. Psychol. Med. 2012, 42, 1203–1215.
    13. Battaglia, S.; Thayer, J.F. Functional Interplay between Central and Autonomic Nervous Systems in Human Fear Conditioning. Trends Neurosci. 2022, 45, 504–506.
    14. Battaglia, S.; Orsolini, S.; Borgomaneri, S.; Barbieri, R.; Diciotti, S.; di Pellegrino, G. Characterizing Cardiac Autonomic Dynamics of Fear Learning in Humans. Psychophysiology 2022, e14122.
    15. Han, K.M.; Ham, B.J. How Inflammation Affects the Brain in Depression: A Review of Functional and Structural MRI Studies. J. Clin. Neurol. 2021, 17, 503.
    16. Burrows, K.; Stewart, J.L.; Kuplicki, R.; Figueroa-Hall, L.; Spechler, P.A.; Zheng, H.; Guinjoan, S.M.; Savitz, J.B.; Kent Teague, T.; Paulus, M.P. Elevated Peripheral Inflammation Is Associated with Attenuated Striatal Reward Anticipation in Major Depressive Disorder. Brain. Behav. Immun. 2021, 93, 214.
    17. Tanaka, M.; Szabó, Á.; Spekker, E.; Polyák, H.; Tóth, F.; Vécsei, L. Mitochondrial Impairment: A Common Motif in Neuropsychiatric Presentation? The Link to the Tryptophan–Kynurenine Metabolic System. Cells 2022, 11, 2607.
    18. Raison, C.L.; Rutherford, R.E.; Woolwine, B.J.; Shuo, C.; Schettler, P.; Drake, D.F.; Haroon, E.; Miller, A.H. A Randomized Controlled Trial of the Tumor Necrosis Factor Antagonist Infliximab for Treatment-Resistant Depression: The Role of Baseline Inflammatory Biomarkers. JAMA Psychiatr. 2013, 70, 31–41.
    19. Zajkowska, Z.E.; Englund, A.; Zunszain, P.A. Towards a Personalized Treatment in Depression: Endocannabinoids, Inflammation and Stress Response. Pharmacogenomics 2014, 15, 687–698.
    20. Łojko, D.; Rybakowski, J.K. Atypical Depression: Current Perspectives. Neuropsychiatr. Dis. Treat. 2017, 13, 2447.
    21. Lamers, F.; De Jonge, P.; Nolen, W.A.; Smit, J.H.; Zitman, F.G.; Beekman, A.T.F.; Penninx, B.W.J.H. Identifying Depressive Subtypes in a Large Cohort Study: Results from the Netherlands Study of Depression and Anxiety (NESDA). J. Clin. Psychiatr. 2010, 71, 1582–1589.
    22. Maes, M.; Berk, M.; Goehler, L.; Song, C.; Anderson, G.; Gałecki, P.; Leonard, B. Depression and Sickness Behavior Are Janus-Faced Responses to Shared Inflammatory Pathways. BMC Med. 2012, 10, 66.
    23. Beurel, E.; Toups, M.; Nemeroff, C.B. The Bidirectional Relationship of Depression and Inflammation: Double Trouble. Neuron 2020, 107, 234.
    24. Strawbridge, R.; Hodsoll, J.; Powell, T.R.; Hotopf, M.; Hatch, S.L.; Breen, G.; Cleare, A.J. Inflammatory Profiles of Severe Treatment-Resistant Depression. J. Affect. Disord. 2019, 246, 42–51.
    25. Miller, A.H.; Raison, C.L. The Role of Inflammation in Depression: From Evolutionary Imperative to Modern Treatment Target. Nat. Rev. Immunol. 2016, 16, 22–34.
    26. Ghlichloo, I.; Gerriets, V. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2022.
    27. Mendlewicz, J.; Kriwin, P.; Oswald, P.; Souery, D.; Alboni, S.; Brunello, N. Shortened Onset of Action of Antidepressants in Major Depression Using Acetylsalicylic Acid Augmentation: A Pilot Open-Label Study. Int. Clin. Psychopharmacol. 2006, 21, 227–231.
    28. Hu, K.; Sjölander, A.; Lu, D.; Walker, A.K.; Sloan, E.K.; Fall, K.; Valdimarsdóttir, U.; Hall, P.; Smedby, K.E.; Fang, F. Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs and Depression, Anxiety, and Stress-Related Disorders Following a Cancer Diagnosis: A Nationwide Register-Based Cohort Study. BMC Med. 2020, 18, 238.
    29. Ghanizadeh, A.; Hedayati, A. Augmentation of Citalopram with Aspirin for Treating Major Depressive Disorder, a Double Blind Randomized Placebo Controlled Clinical Trial. Antiinflamm. Antiallergy. Agents Med. Chem. 2014, 13, 108–111.
    30. Sepehrmanesh, Z.; Fahimi, H.; Akasheh, G.; Davoudi, M.; Gilasi, H.; Ghaderi, A. The Effects of Combined Sertraline and Aspirin Therapy on Depression Severity among Patients with Major Depressive Disorder: A Randomized Clinical Trial. Electron. Physician 2017, 9, 5770.
    31. Zdanowicz, N.; Reynaert, C.; Jacques, D.; Lepiece, B.; Dubois, T. Selective Serotonergic (SSRI) Versus Noradrenergic (SNRI) Reuptake Inhibitors with and without Acetylsalicylic Acid in Major Depressive Disorder. Psychiatr. Danub. 2017, 29 (Suppl. 3), 270–273.
    32. Berk, M.; Mohebbi, M.; Dean, O.M.; Cotton, S.M.; Chanen, A.M.; Dodd, S.; Ratheesh, A.; Amminger, G.P.; Phelan, M.; Weller, A.; et al. Youth Depression Alleviation with Anti-Inflammatory Agents (YoDA-A): A Randomised Clinical Trial of Rosuvastatin and Aspirin. BMC Med. 2020, 18, 16.
    33. Berk, M.; Woods, R.L.; Nelson, M.R.; Shah, R.C.; Reid, C.M.; Storey, E.; Fitzgerald, S.; Lockery, J.E.; Wolfe, R.; Mohebbi, M.; et al. Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial. JAMA Psychiatr. 2020, 77, 1012–1020.
    34. Kim, H.; Kim, J.; Jung, J. The Association between Aspirin Use and Depression: A Systematic Review and Meta-analysis of Observational Studies. Pharmacoepidemiol. Drug Saf. 2020, 29, 613–622.
    35. Ng, Q.X.; Ramamoorthy, K.; Loke, W.; Lee, M.W.L.; Yeo, W.S.; Lim, D.Y.; Sivalingam, V. Clinical Role of Aspirin in Mood Disorders: A Systematic Review. Brain Sci. 2019, 9, 296.
    36. Iyengar, R.L.; Gandhi, S.; Aneja, A.; Thorpe, K.; Razzouk, L.; Greenberg, J.; Mosovich, S.; Farkouh, M.E. NSAIDs Are Associated with Lower Depression Scores in Patients with Osteoarthritis. Am. J. Med. 2013, 126, 1017.e11–1017.e18.
    37. Fields, C.; Drye, L.; Vaidya, V.; Lyketsos, C.; ADAPT Research Group. Celecoxib or Naproxen Treatment Does Not Benefit Depressive Symptoms in Persons Age 70 and Older: Findings from a Randomized Controlled Trial. Am. J. Geriatr. Psychiatr. 2012, 20, 505–513.
    38. Müller, N.; Schwarz, M.J.; Dehning, S.; Douhe, A.; Cerovecki, A.; Goldstein-Müller, B.; Spellmann, I.; Hetzel, G.; Maino, K.; Kleindienst, N.; et al. The Cyclooxygenase-2 Inhibitor Celecoxib Has Therapeutic Effects in Major Depression: Results of a Double-Blind, Randomized, Placebo Controlled, Add-on Pilot Study to Reboxetine. Mol. Psychiatr. 2006, 11, 680–684.
    39. Akhondzadeh, S.; Jafari, S.; Raisi, F.; Nasehi, A.A.; Ghoreishi, A.; Salehi, B.; Mohebbi-Rasa, S.; Raznahan, M.; Kamalipour, A. Clinical Trial of Adjunctive Celecoxib Treatment in Patients with Major Depression: A Double Blind and Placebo Controlled Trial. Depress. Anxiety 2009, 26, 607–611.
    40. Alamdarsaravi, M.; Ghajar, A.; Noorbala, A.A.; Arbabi, M.; Emami, A.; Shahei, F.; Mirzania, M.; Jafarinia, M.; Afarideh, M.; Akhondzadeh, S. Efficacy and Safety of Celecoxib Monotherapy for Mild to Moderate Depression in Patients with Colorectal Cancer: A Randomized Double-Blind, Placebo Controlled Trial. Psychiatr. Res. 2017, 255, 59–65.
    41. Jafari, S.; Ashrafizadeh, S.G.; Zeinoddini, A.; Rasoulinejad, M.; Entezari, P.; Seddighi, S.; Akhondzadeh, S. Celecoxib for the Treatment of Mild-to-Moderate Depression Due to Acute Brucellosis: A Double-Blind, Placebo-Controlled, Randomized Trial. J. Clin. Pharm. Ther. 2015, 40, 441–446.
    42. Abbasi, S.H.; Hosseini, F.; Modabbernia, A.; Ashrafi, M.; Akhondzadeh, S. Effect of Celecoxib Add-on Treatment on Symptoms and Serum IL-6 Concentrations in Patients with Major Depressive Disorder: Randomized Double-Blind Placebo-Controlled Study. J. Affect. Disord. 2012, 141, 308–314.
    43. Simon, M.S.; Burger, B.; Weidinger, E.; Arteaga-Henríquez, G.; Zill, P.; Musil, R.; Drexhage, H.A.; Müller, N. Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline—Results From a Randomized Controlled Clinical Trial. Front. Psychiatr. 2021, 12, 615261.
    44. Baune, B.T.; Sampson, E.; Louise, J.; Hori, H.; Schubert, K.O.; Clark, S.R.; Mills, N.T.; Fourrier, C. No Evidence for Clinical Efficacy of Adjunctive Celecoxib with Vortioxetine in the Treatment of Depression: A 6-Week Double-Blind Placebo Controlled Randomized Trial. Eur. Neuropsychopharmacol. 2021, 53, 34–46.
    45. Adzic, M.; Brkic, Z.; Mitic, M.; Francija, E.; Jovicic, M.J.; Radulovic, J.; Maric, N.P. Therapeutic Strategies for Treatment of Inflammation-Related Depression. Curr. Neuropharmacol. 2018, 16, 176–209.
    46. Köhler, O.; Benros, M.E.; Nordentoft, M.; Farkouh, M.E.; Iyengar, R.L.; Mors, O.; Krogh, J. Effect of Anti-Inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects a Systematic Review and Meta-Analysis of Randomized Clinical Trials. JAMA Psychiatr. 2014, 71, 1381–1391.
    47. Kohler, O.; Krogh, J.; Mors, O.; Eriksen Benros, M. Inflammation in Depression and the Potential for Anti-Inflammatory Treatment. Curr. Neuropharmacol. 2016, 14, 732–742.
    48. Wium-Andersen, I.K.; Wium-Andersen, M.K.; Jørgensen, M.B.; Osler, M. Anti-Inflammatory Treatment and Risk for Depression. J. Psychiatr. Neurosci. 2017, 42, 320–330.
    49. Musil, R.; Schwarz, M.J.; Riedel, M.; Dehning, S.; Cerovecki, A.; Spellmann, I.; Arolt, V.; Müller, N. Elevated Macrophage Migration Inhibitory Factor and Decreased Transforming Growth Factor-Beta Levels in Major Depression—No Influence of Celecoxib Treatment. J. Affect. Disord. 2011, 134, 217–225.
    50. Majd, M.; Hashemian, F.; Hosseinib, S.M.; Shariatpanahi, M.V.; Sharifid, A. A Randomized, Double-Blind, Placebo-Controlled Trial of Celecoxib Augmentation of Sertraline in Treatment of Drug-Naive Depressed Women: A Pilot Study. Iran. J. Pharm. Res. IJPR 2015, 14, 891.
    51. Krause, D.; Myint, A.M.; Schuett, C.; Musil, R.; Dehning, S.; Cerovecki, A.; Riedel, M.; Arolt, V.; Schwarz, M.J.; Müller, N. High Kynurenine (a Tryptophan Metabolite) Predicts Remission in Patients with Major Depression to Add-on Treatment with Celecoxib. Front. Psychiatr. 2017, 8, 16.
    52. Mohammadinejad, P.; Arya, P.; Esfandbod, M.; Kaviani, A.; Najafi, M.; Kashani, L.; Zeinoddini, A.; Emami, S.A.; Akhondzadeh, S. Celecoxib Versus Diclofenac in Mild to Moderate Depression Management among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial. Ann. Pharmacother. 2015, 49, 953–961.
    53. Webers, C.; Stolwijk, C.; Schiepers, O.; Schoonbrood, T.; Van Tubergen, A.; Landewé, R.; Van Der Heijde, D.; Boonen, A. Infliximab Treatment Reduces Depressive Symptoms in Patients with Ankylosing Spondylitis: An Ancillary Study to a Randomized Controlled Trial (ASSERT). Arthritis Res. Ther. 2020, 22, 1–11.
    54. Tyring, S.; Gottlieb, A.; Papp, K.; Gordon, K.; Leonardi, C.; Wang, A.; Lalla, D.; Woolley, M.; Jahreis, A.; Zitnik, R.; et al. Etanercept and Clinical Outcomes, Fatigue, and Depression in Psoriasis: Double-Blind Placebo-Controlled Randomised Phase III Trial. Lancet 2006, 367, 29–35.
    55. Scheinfeld, N.; Sundaram, M.; Teixeira, H.; Gu, Y.; Okun, M. Reduction in Pain Scores and Improvement in Depressive Symptoms in Patients with Hidradenitis Suppurativa Treated with Adalimumab in a Phase 2, Randomized, Placebo-Controlled Trial. Dermatol. Online J. 2016, 22, 2.
    56. Tyring, S.; Bagel, J.; Lynde, C.; Klekotka, P.; Thompson, E.H.Z.; Gandra, S.R.; Shi, Y.; Kricorian, G. Patient-Reported Outcomes in Moderate-to-Severe Plaque Psoriasis with Scalp Involvement: Results from a Randomized, Double-Blind, Placebo-Controlled Study of Etanercept. J. Eur. Acad. Dermatol. Venereol. 2013, 27, 125–128.
    57. Loftus, E.V.; Feagan, B.G.; Colombel, J.F.; Rubin, D.T.; Wu, E.Q.; Yu, A.P.; Pollack, P.F.; Chao, J.; Mulani, P. Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients with Crohn’s Disease: Patient-Reported Outcomes of the CHARM Trial. Am. J. Gastroenterol. 2008, 103, 3132–3141.
    58. Menter, A.; Augustin, M.; Signorovitch, J.; Yu, A.P.; Wu, E.Q.; Gupta, S.R.; Bao, Y.; Mulani, P. The Effect of Adalimumab on Reducing Depression Symptoms in Patients with Moderate to Severe Psoriasis: A Randomized Clinical Trial. J. Am. Acad. Dermatol. 2010, 62, 812–818.
    59. Simpson, E.L.; Gadkari, A.; Worm, M.; Soong, W.; Blauvelt, A.; Eckert, L.; Wu, R.; Ardeleanu, M.; Graham, N.M.H.; Pirozzi, G.; et al. Dupilumab Therapy Provides Clinically Meaningful Improvement in Patient-Reported Outcomes (PROs): A Phase IIb, Randomized, Placebo-Controlled, Clinical Trial in Adult Patients with Moderate to Severe Atopic Dermatitis (AD). J. Am. Acad. Dermatol. 2016, 75, 506–515.
    60. de Bruin-Weller, M.; Thaçi, D.; Smith, C.H.; Reich, K.; Cork, M.J.; Radin, A.; Zhang, Q.; Akinlade, B.; Gadkari, A.; Eckert, L.; et al. Dupilumab with Concomitant Topical Corticosteroid Treatment in Adults with Atopic Dermatitis with an Inadequate Response or Intolerance to Ciclosporin A or When This Treatment Is Medically Inadvisable: A Placebo-Controlled, Randomized Phase III Clinical Trial (LIBERTY AD CAFÉ). Br. J. Dermatol. 2018, 178, 1083–1101.
    61. Cork, M.J.; Eckert, L.; Simpson, E.L.; Armstrong, A.; Barbarot, S.; Puig, L.; Girolomoni, G.; de Bruin-Weller, M.; Wollenberg, A.; Kataoka, Y.; et al. Dupilumab Improves Patient-Reported Symptoms of Atopic Dermatitis, Symptoms of Anxiety and Depression, and Health-Related Quality of Life in Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from the Randomized Trials SOLO 1 and SOLO 2. J. Dermatolog. Treat. 2020, 31, 606–614.
    62. Griffiths, C.E.M.; Fava, M.; Miller, A.H.; Russell, J.; Ball, S.G.; Xu, W.; Acharya, N.; Rapaport, M.H. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies. Psychother. Psychosom. 2017, 86, 260–267.
    63. Gordon, K.B.; Armstrong, A.W.; Han, C.; Foley, P.; Song, M.; Wasfi, Y.; You, Y.; Shen, Y.K.; Reich, K. Anxiety and Depression in Patients with Moderate-to-Severe Psoriasis and Comparison of Change from Baseline after Treatment with Guselkumab vs. Adalimumab: Results from the Phase 3 VOYAGE 2 Study. J. Eur. Acad. Dermatol. Venereol. 2018, 32, 1940–1949.
    64. Langley, R.G.; Feldman, S.R.; Han, C.; Schenkel, B.; Szapary, P.; Hsu, M.C.; Ortonne, J.P.; Gordon, K.B.; Kimball, A.B. Ustekinumab Significantly Improves Symptoms of Anxiety, Depression, and Skin-Related Quality of Life in Patients with Moderate-to-Severe Psoriasis: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Trial. J. Am. Acad. Dermatol. 2010, 63, 457–465.
    65. Patten, S.B.; Barbui, C. Drug-Induced Depression: A Systematic Review to Inform Clinical Practice. Psychother. Psychosom. 2004, 73, 207–215.
    66. Arana, G.W.; Santos, A.B.; Laraia, M.T.; McLeod-Bryant, S.; Beale, M.D.; Rames, L.J.; Roberts, J.M.; Dias, J.K.; Molloy, M. Dexamethasone for the Treatment of Depression: A Randomized, Placebo-Controlled, Double-Blind Trial. Am. J. Psychiatr. 1995, 152, 265–267.
    67. DeBattista, C.; Posener, J.A.; Kalehzan, B.M.; Schatzberg, A.F. Acute Antidepressant Effects of Intravenous Hydrocortisone and CRH in Depressed Patients: A Double-Blind, Placebo-Controlled Study. Am. J. Psychiatr. 2000, 157, 1334–1337.
    68. Kok, L.; Hillegers, M.H.; Veldhuijzen, D.S.; Cornelisse, S.; Nierich, A.P.; Van Der Maaten, J.M.; Rosseel, P.M.; Hofland, J.; Sep, M.S.; Dieleman, J.M.; et al. The Effect of Dexamethasone on Symptoms of Posttraumatic Stress Disorder and Depression After Cardiac Surgery and Intensive Care Admission: Longitudinal Follow-Up of a Randomized Controlled Trial. Crit. Care Med. 2016, 44, 512–520.
    69. Bates, S.M.; Hill, V.A.; Anderson, J.B.; Chapple, C.R.; Spence, R.; Ryan, C.; Talbot, M.D. A Prospective, Randomized, Double-Blind Trial to Evaluate the Role of a Short Reducing Course of Oral Corticosteroid Therapy in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. BJU Int. 2007, 99, 355–359.
    70. Yennurajalingam, S.; Frisbee-Hume, S.; Palmer, J.L.; Delgado-Guay, M.O.; Bull, J.; Phan, A.T.; Tannir, N.M.; Litton, J.K.; Reddy, A.; Hui, D.; et al. Reduction of Cancer-Related Fatigue with Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients with Advanced Cancer. J. Clin. Oncol. 2013, 31, 3076–3082.
    71. Hang, X.; Zhang, Y.; Li, J.; Li, Z.; Zhang, Y.; Ye, X.; Tang, Q.; Sun, W. Comparative Efficacy and Acceptability of Anti-Inflammatory Agents on Major Depressive Disorder: A Network Meta-Analysis. Front. Pharmacol. 2021, 12, 691200.
    More
    Information
    Subjects: Neurosciences
    Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , , ,
    View Times: 40
    Revisions: 3 times (View History)
    Update Time: 07 Nov 2022
    Table of Contents
      1000/1000

      Confirm

      Are you sure to Delete?

      Video Upload Options

      Do you have a full video?
      Cite
      If you have any further questions, please contact Encyclopedia Editorial Office.
      Dogaru, I.; Puiu, M.G.; Manea, M.; Dionisie, V. Conventional Anti-Inflammatory Drugs of Major Depressive Disorder. Encyclopedia. Available online: https://encyclopedia.pub/entry/33103 (accessed on 01 December 2022).
      Dogaru I, Puiu MG, Manea M, Dionisie V. Conventional Anti-Inflammatory Drugs of Major Depressive Disorder. Encyclopedia. Available at: https://encyclopedia.pub/entry/33103. Accessed December 01, 2022.
      Dogaru, Ioana-Alexandra, Maria Gabriela Puiu, Mirela Manea, Vlad Dionisie. "Conventional Anti-Inflammatory Drugs of Major Depressive Disorder," Encyclopedia, https://encyclopedia.pub/entry/33103 (accessed December 01, 2022).
      Dogaru, I., Puiu, M.G., Manea, M., & Dionisie, V. (2022, November 04). Conventional Anti-Inflammatory Drugs of Major Depressive Disorder. In Encyclopedia. https://encyclopedia.pub/entry/33103
      Dogaru, Ioana-Alexandra, et al. ''Conventional Anti-Inflammatory Drugs of Major Depressive Disorder.'' Encyclopedia. Web. 04 November, 2022.
      Top
      Feedback